These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 17846007)

  • 41. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
    Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
    Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer.
    Oliveira SC; Machado KK; Sabbaga J; Hoff PM
    Cancer J; 2010; 16(3):220-5. PubMed ID: 20526100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
    Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
    J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
    Ellis LM; Rosen L; Gordon MS
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The horizon of antiangiogenic therapy for colorectal cancer.
    Olszewski AJ; Grossbard ML; Kozuch PS
    Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spotlight on bevacizumab in metastatic colorectal cancer.
    McCormack PL; Keam SJ
    BioDrugs; 2008; 22(5):339-41. PubMed ID: 18778115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
    Gamboa EO; Rehmus EH; Haller N
    Clin Colorectal Cancer; 2010 Jan; 9(1):55-8. PubMed ID: 20100690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab in the treatment of colorectal cancer.
    Mulcahy MF; Benson AB
    Expert Opin Biol Ther; 2005 Jul; 5(7):997-1005. PubMed ID: 16018743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
    Franson PJ; Lapka DV
    Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
    Cartwright TH
    Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting vascular endothelial growth factor in colorectal cancer.
    Berlin JD
    Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):13-5. PubMed ID: 12199627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
    André T; Chibaudel B
    Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of bevacizumab in patients with metastatic breast cancer.
    Hamilton EP; Blackwell KL
    Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
    Zondor SD; Medina PJ
    Ann Pharmacother; 2004; 38(7-8):1258-64. PubMed ID: 15187215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
    Fakih M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
    Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
    Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.